drugset
drugset / Trial / NCT04123574

A Pilot Study of BXCL701 in Patients With Pancreatic Cancer

NCT04123574 ↗

Phase 0 Withdrawn BioXcel Therapeutics Inc IQVIA Biotech · collab
NaSingle-groupOpen-labelTreatment

Summary

A study to assess the biochemical and immunomodulatory effects of BXCL701 in pancreatic cancer.

Timeline

Start
2019-10-15
Primary completion
2021-12-06
Completion
2021-12-06

Outcome

Outcome not reported

Stopped: “No longer relevant to field”

Drugs

EvaluationDrugModalityDoseRoute
Subject talabostat Small molecule 0.3 mg Oral

Indications

malignant pancreatic neoplasm